Skip to main content
. 2024 May 7;13(2):39. doi: 10.3390/antib13020039

Figure 3.

Figure 3

VH20-TCE (VH20-OKT-Fc) structure and T cell-mediated cytotoxicity. (A) The scheme of the VH20-TCE. VH20-TCE consists of VH20 fusing at the N terminus of OKT3 scFv followed by linking to the human IgG1 Fc. (B) ELISA results of VH20-TCE binding to ALK extracellular domain with BSA as a negative control. Samples were tested in triplicate and error bars denote ± SD, n = 3. (C) FACS results of VH20-TCE binding to 293T, 293T-ALK and PanT cells. VH20-TCE specifically binds to 293T-ALK and PanT cells. No off–target binding to 293T cells was detected. (D) Cytotoxicity of T cells (activated) to 293T and 293T-ALK cells induced by VH20-TCE. Potent killing efficacy towards 293T-ALK cells was detected. (E) Cytotoxicity of T cells to IMR−32, SH-SY5Y and SK-N-AS cells induced by VH20-TCE. Potent killing efficacy towards IMR-32 and SH-SY5Y cells was detected. TCE cytotoxicity assays were detected in triplicate and error bars denote ± SD, n = 3.